Maple Grove, Minnesota, United States, November 10, 2026
Francis Medical, Inc., a medical technology company specializing in minimally invasive therapies for urological cancers, has announced a strategic financing agreement led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), the corporate venture capital organization of Johnson & Johnson. The investment will support the company’s commercial expansion and further development of its Vanquish Water Vapor Ablation System, an innovative technology designed to deliver targeted thermal energy to prostate tissue. The financing is expected to strengthen Francis Medical’s commercial infrastructure, expand market access initiatives and increase physician training and education programs across the United States. Importantly, the funding will also support the company’s planned Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA) for the management of clinically localized prostate cancer. Although the financial terms of the agreement were not disclosed, the investment represents an important milestone in the company’s strategy to expand its presence in the urological oncology market.
Johnson & Johnson Investment Supports Commercial Expansion
The strategic financing led by JJDC is intended to help Francis Medical transition from its limited commercial launch toward a broader U.S. market presence. The investment will provide resources to expand its commercial organization, strengthen distribution and market access activities, and improve physician education and training. These initiatives are particularly important for minimally invasive medical technologies that require specialized clinical expertise and appropriate procedural training. Francis Medical aims to increase awareness and adoption of the Vanquish System among urologists and healthcare institutions while continuing to generate clinical evidence supporting its potential application in prostate cancer management. Mike Kujak, President and Chief Executive Officer of Francis Medical, described the financing as a pivotal development in the company’s growth strategy. He emphasized that the support from Johnson & Johnson Innovation would help accelerate commercial development while enabling the company to pursue important clinical and regulatory milestones. The investment also highlights continued strategic interest in innovative medical technologies designed to improve cancer treatment options and patient care.
Vanquish System Uses Targeted Water Vapor Ablation Technology
The Vanquish Water Vapor Ablation System is a transurethral, ultrasound-guided and electromagnetically guided thermotherapy platform developed to ablate targeted prostate tissue using convective water vapor energy. The system is designed to deliver thermal energy precisely within the prostate, with the objective of treating targeted tissue while minimizing damage to surrounding structures associated with urinary and sexual function. Unlike conventional approaches that may involve more extensive treatment of prostate tissue, the Vanquish technology is being investigated as a minimally invasive focal treatment strategy. The system received FDA 510(k) clearance in November 2025 as a tool for thermal ablation of targeted prostate tissue through a transurethral approach. However, this clearance does not constitute FDA approval for treating prostate cancer. The company is pursuing a separate PMA pathway to obtain a specific indication for the management of clinically localized prostate cancer. This regulatory distinction is important because the FDA has not evaluated the Vanquish System for the treatment of prostate cancer or its long-term cancer treatment outcomes.
Advertisement
VAPOR 2 Clinical Study Reports Encouraging Preliminary Findings
Francis Medical continues to evaluate the Vanquish System through its VAPOR 2 pivotal clinical study, a prospective, multicenter, single-arm investigation involving 235 patients with intermediate-risk, localized prostate cancer across 26 clinical sites in the United States. Initial findings from the first 110 patients were recently published in The Journal of Urology. According to the company, 91% of patients had no clinically significant MRI-visible cancer in the treated area following a single procedure. The analysis also reported no device-related serious adverse events among these patients. Patient-reported outcomes indicated that 93% were satisfied or extremely satisfied with the procedure, while 94% considered receiving the treatment a wise decision. These preliminary results provide important clinical evidence supporting further investigation of the technology. However, the study remains ongoing, and patients will continue to be followed for up to five years to evaluate longer-term clinical outcomes, safety and durability of treatment response. The additional follow-up data will be important for supporting the company’s planned regulatory submission and assessing the potential role of Vanquish in prostate cancer management. Overall, the strategic financing from Johnson & Johnson Innovation represents an important milestone for Francis Medical as it advances its commercial and regulatory objectives. By strengthening its market presence, expanding physician training and continuing the VAPOR 2 clinical program, the company aims to bring its minimally invasive water vapor ablation technology to a broader healthcare audience. The planned FDA PMA submission and ongoing clinical evidence generation will be important steps in determining whether Vanquish can become an additional treatment option for appropriately selected patients with localized prostate cancer.
Source: Francis Medical press release
